MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Non-motor Scales"

  • MDS Virtual Congress 2020

    Progression in Parkinson’s disease: Variation in motor and non-motor symptoms severity and predictors of decline in cognition, motor function, incapacity and Health Related Quality of Life

    P. Bugalho, F. Ladeira, R. Barbosa, J. Marto, C. Borbinha, M. Salavisa, M. Saraiva, L. Conceição, M. Fernandes, B. Meira (Lisboa, Portugal)

    Objective: Assess the progression of motor and non-motor symptoms in Parkinson's Disease (PD) and predictors of cognitive, motor, activities of daily living (ADL) and Health…
  • MDS Virtual Congress 2020

    Functional Hearing Impairment Common In Parkinson’s Disease: Insights From A Pilot Study

    D. Nene, M. Choi, A. Yu, M.S Mirian, J.A Small, L.M Jenstad, S. Appel-Cresswell (Vancouver, BC, Canada)

    Objective: The primary objective of this pilot study was to investigate hearing and its relationship to the neuropsychiatric profile, cognition and quality of life in…
  • MDS Virtual Congress 2020

    Effects of Nabilone on non-motor symptoms of Parkinson´s Disease: A randomised placebo-controlled study (The NMS-Nab Study)

    M. Peball, F. Krismer, H.G Knaus, A. Djamshidian, M. Werkmann, F. Carbone, P. Ellmerer, B. Heim, K. Marini, D. Valent, G. Goebel, H. Ulmer, H. Stockner, G.K Wenning, R. Stolz, K. Krejcy, W. Poewe, K. Seppi (Innsbruck, Austria)

    Objective: To investigate the effects of the synthetic cannabinoid nabilone for the treatment of non-motor symptoms in Parkinson´s disease (PD) in a controlled fashion. Background:…
  • MDS Virtual Congress 2020

    Value of nocturnal hypokinesia screening concerning the quality of life and clinical features in Parkinson’s disease

    J. Choi, J. Lee, C. Shin, D. Yoo, J. Im, K. Woo, H. Kim, T. Ahn, J. Kim, B. Jeon (Seoul, Republic of Korea)

    Objective: To assess nocturnal hypokinesia and its relationship with clinical features and quality of life (QoL) in patients with Parkinson’s disease (PD). Background: The nocturnal…
  • MDS Virtual Congress 2020

    Profile of non motor symptoms in familial Parkinson’s disease

    A. Patwardhan, P. Pal, R. Yadav, N. Kamble (Bangalore, India)

    Objective: Non motor symptoms have a significant contribution to the quality of life of patients with Parkinson’s disease.The aim of the study was to assess the…
  • MDS Virtual Congress 2020

    Helicobacter pylori eradication in Parkinson’s disease: A double-blind randomized placebo-controlled study

    A.H Tan, S.Y Lim, S. Mahadeva, M.F Loke, J.S Vadivelu, C. Marras, S.H Fox, A.E Lang (Kuala Lumpur, Malaysia)

    Objective: To evaluate the effects of Helicobacter pylori eradication on PD symptoms. Background: Globally, H. pylori infection remains a common problem. Cross-sectional studies in Parkinson's disease (PD)…
  • MDS Virtual Congress 2020

    Non-motor Symptoms in Advanced- vs Non-advanced Parkinson’s Disease: A Subgroup Analysis of the OBSERVE-PD Observational Study

    A. Fasano, L. Bergmann, V. SC Fung, K. Onuk, K. Seppi, Z. Pirtosek (Toronto, ON, Canada)

    Objective: To report intercountry differences in non-motor symptoms in patients with advanced Parkinson’s Disease (APD) vs non-APD. Background: There is no standard criteria for the…
  • MDS Virtual Congress 2020

    RBD and autonomic dysfunction in newly diagnosed Parkinson’s disease patients

    G.M Riboldi, L. Pan, K. dePaiva Lopes, K. Watkins, T. Raj, U. Kang (New York, NY, USA)

    Objective: To determine whether newly diagnosed Parkinson’s disease (PD) patients with REM sleep behavior disorder (RBD) are more likely to have symptoms of autonomic dysfunction.…
  • MDS Virtual Congress 2020

    Effect of Lactobacillus casei supplementation on clinical response, gut microbiota and faecal metabolites in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial

    X.D Yang, X.Q He, S.Q Xu, VV. Qian, Y. Zhang, YY. Song, Q. Xiao (Shanghai, China)

    Objective: To evaluate the effect of Lactobacillus casei strain Shirota (LcS) supplementation on symptoms, gut microbiota and faecal metabolites in patients with Parkinson's disease (PD).…
  • MDS Virtual Congress 2020

    Serum molecular markers and non-motor symptoms in Parkinson’s disease

    I. González-Aramburu, M. Sierra, J. Infante, S. Jesús Maestre, M. Aguilar, P. Pastor, J. Hernández Vara, S. Escalante, F.J Carrillo Padilla, M. Pueyo, J.M García Moreno, V. Puente, A. Crespo Cuevas, O. de Fábregues-Boixar, B. Solano Vila, T. de Deus-Fonticoba, P. Martínez Martín, P. Mir, D. Santos García (Santander, Spain)

    Objective: The aim of this study was to examine the association between several serum molecular markers and different measures of non-motor symptom burden in PD.…
  • « Previous Page
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • …
  • 51
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • VIT-D and Tics Movement Disorder
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley